AU622630B2 - D-cycloserine and its prodrugs as cognitive enhancers - Google Patents

D-cycloserine and its prodrugs as cognitive enhancers Download PDF

Info

Publication number
AU622630B2
AU622630B2 AU26319/88A AU2631988A AU622630B2 AU 622630 B2 AU622630 B2 AU 622630B2 AU 26319/88 A AU26319/88 A AU 26319/88A AU 2631988 A AU2631988 A AU 2631988A AU 622630 B2 AU622630 B2 AU 622630B2
Authority
AU
Australia
Prior art keywords
hydrido
acceptable salt
dosage form
pharmaceutically
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26319/88A
Other languages
English (en)
Other versions
AU2631988A (en
Inventor
Alex A. Cordi
Gail E. Handelmann
Joseph B. Monahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of AU2631988A publication Critical patent/AU2631988A/en
Application granted granted Critical
Publication of AU622630B2 publication Critical patent/AU622630B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU26319/88A 1987-12-01 1988-11-29 D-cycloserine and its prodrugs as cognitive enhancers Ceased AU622630B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/127,121 US4904681A (en) 1987-12-01 1987-12-01 D-cycloserine and its prodrugs as cognitive enhancers
US127121 1987-12-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU10839/92A Division AU1083992A (en) 1987-12-01 1992-02-10 Formulations of d-cycloserine as cognitive enhancers

Publications (2)

Publication Number Publication Date
AU2631988A AU2631988A (en) 1989-06-01
AU622630B2 true AU622630B2 (en) 1992-04-16

Family

ID=22428413

Family Applications (4)

Application Number Title Priority Date Filing Date
AU26319/88A Ceased AU622630B2 (en) 1987-12-01 1988-11-29 D-cycloserine and its prodrugs as cognitive enhancers
AU28130/89A Abandoned AU2813089A (en) 1987-12-01 1988-12-01 Use of a glycine b partial agonist for memory and learning enhancement or treatment of a cognitive disorder
AU10839/92A Abandoned AU1083992A (en) 1987-12-01 1992-02-10 Formulations of d-cycloserine as cognitive enhancers
AU77467/94A Abandoned AU7746794A (en) 1987-12-01 1994-10-26 Formulations of D-cycloserine as cognitive enhancers

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU28130/89A Abandoned AU2813089A (en) 1987-12-01 1988-12-01 Use of a glycine b partial agonist for memory and learning enhancement or treatment of a cognitive disorder
AU10839/92A Abandoned AU1083992A (en) 1987-12-01 1992-02-10 Formulations of d-cycloserine as cognitive enhancers
AU77467/94A Abandoned AU7746794A (en) 1987-12-01 1994-10-26 Formulations of D-cycloserine as cognitive enhancers

Country Status (20)

Country Link
US (1) US4904681A (enExample)
EP (2) EP0319824B1 (enExample)
JP (2) JPH0621065B2 (enExample)
KR (1) KR0134198B1 (enExample)
AT (1) ATE68698T1 (enExample)
AU (4) AU622630B2 (enExample)
CA (1) CA1328617C (enExample)
DE (1) DE3865817D1 (enExample)
DK (1) DK173589B1 (enExample)
ES (1) ES2040314T3 (enExample)
FI (1) FI885559A0 (enExample)
GR (1) GR3003571T3 (enExample)
IE (1) IE61825B1 (enExample)
IL (1) IL88531A (enExample)
NO (1) NO885337D0 (enExample)
NZ (1) NZ227131A (enExample)
PH (1) PH26467A (enExample)
PT (1) PT89109B (enExample)
WO (1) WO1989005144A1 (enExample)
ZA (1) ZA888981B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5066665A (en) * 1990-05-21 1991-11-19 Warner-Lambert Co. Substituted isoxazolidin-3-ones and derivatives thereof acting at muscarinic receptors
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
NZ260302A (en) * 1994-04-13 1996-05-28 New Zealand Meat Ind Res Inst Treating bait aversion by including substances which disrupt the associative learning process into bait compositions
AU4128896A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
AU4019395A (en) 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
US5731348A (en) * 1995-02-15 1998-03-24 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
JP2000501707A (ja) * 1995-12-07 2000-02-15 ジャビット，ダニエル・シー グリシン捕捉性アンタゴニストを用いる拒絶性および認知性精神分裂病症候群の処置
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
FR2742748B1 (fr) * 1995-12-21 1998-01-30 Adir Nouveau derive de 4-imidazolidinone, son procede de preparation et les compositions pharmaceutiques qui le contiennent
KR100396114B1 (ko) * 1996-10-31 2003-11-20 동아제약 주식회사 D-시클로세린의 제조방법
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders
ES2262322T3 (es) 1998-06-10 2006-11-16 Meiji Seika Kaisha, Ltd. Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar.
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20060252761A1 (en) * 2001-03-29 2006-11-09 Michael Davis Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
WO2002078629A2 (en) * 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EP1389181A4 (en) 2001-04-02 2005-10-19 Panorama Res Inc NITROXIDE AND NITRONE ANTIOXIDANTS AS THERAPEUTICS
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
EP1660634A4 (en) * 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
JP5702288B2 (ja) 2008-09-18 2015-04-15 ノースウエスタン ユニバーシティ Ｎｍｄａレセプターモジュレータ及びその用途
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
AU2011215704B2 (en) 2010-02-11 2015-07-23 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CA2899010A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX375286B (es) 2013-01-29 2025-03-06 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
LT2951183T (lt) 2013-01-29 2019-05-27 Aptinyx Inc. Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP6823083B2 (ja) 2016-05-19 2021-01-27 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
PE20190504A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
ES2974090T3 (es) 2016-08-01 2024-06-25 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de NMDA de espirolactama y métodos de uso de los mismos
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
JP7210599B2 (ja) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung

Also Published As

Publication number Publication date
JPH05201859A (ja) 1993-08-10
NO885337D0 (no) 1988-11-30
PT89109A (pt) 1989-12-29
ATE68698T1 (de) 1991-11-15
KR890009392A (ko) 1989-08-01
CA1328617C (en) 1994-04-19
FI885559A0 (fi) 1988-11-30
ZA888981B (en) 1990-01-31
IE61825B1 (en) 1994-11-30
DE3865817D1 (enExample) 1991-11-28
EP0319824B1 (en) 1991-10-23
NZ227131A (en) 1991-09-25
EP0421997A1 (en) 1991-04-17
AU1083992A (en) 1992-05-07
IL88531A (en) 1993-02-21
US4904681A (en) 1990-02-27
JPH01193220A (ja) 1989-08-03
PH26467A (en) 1992-07-27
GR3003571T3 (enExample) 1993-03-16
DK669088A (da) 1989-06-02
IL88531A0 (en) 1989-06-30
PT89109B (pt) 1993-07-30
KR0134198B1 (ko) 1998-04-21
WO1989005144A1 (en) 1989-06-15
ES2040314T3 (es) 1995-04-01
DK669088D0 (da) 1988-11-30
AU7746794A (en) 1995-01-05
AU2813089A (en) 1989-07-05
DK173589B1 (da) 2001-04-02
IE883567L (en) 1989-06-01
AU2631988A (en) 1989-06-01
JPH0621065B2 (ja) 1994-03-23
EP0319824A1 (en) 1989-06-14

Similar Documents

Publication Publication Date Title
US4904681A (en) D-cycloserine and its prodrugs as cognitive enhancers
EP0387867B1 (en) Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
AU679492B2 (en) Methods for the improvement of cognition with functional antagonists of the glycine NMDA receptor complex
US5260324A (en) Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5187171A (en) Use of a glycine b partial agonist as an antipsychotic
US5468763A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US5087633A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US6656962B2 (en) Use of amino-isoxazolidone compounds for improvement of lexical priming
US5866597A (en) Use of triazine compounds for the treatment of memory and learning disorders
AP478A (en) Use of triazine compounds for the treatment of impaired memory and learning disorders.
US20030073730A1 (en) Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury